Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism

被引:35
作者
Unwalla, Rayomand J. [1 ]
Cross, Jason B. [1 ]
Salaniwal, Sumeet [1 ]
Shilling, Adam D. [2 ]
Leung, Louis [2 ]
Kao, John [2 ]
Humblet, Christine [3 ]
机构
[1] Wyeth Ayerst Res, Chem Sci, Collegeville, PA 19426 USA
[2] Wyeth Ayerst Res, Drug Safety & Metab, Collegeville, PA 19426 USA
[3] Wyeth Ayerst Res, Chem Sci, Princeton, NJ 08543 USA
关键词
Cytochrome P450s; CYP2D6; Homology modeling; Molecular docking; HUMAN-LIVER; N-DEMETHYLATION; ACTIVE-SITE; IN-VITRO; CRYSTAL-STRUCTURE; SELECTIVE METABOLISM; ANGSTROM RESOLUTION; ACCURATE DOCKING; DRUG-METABOLISM; FORCE-FIELD;
D O I
10.1007/s10822-010-9336-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CYP2D6 is an important enzyme that is involved in first pass metabolism and is responsible for metabolizing similar to 25% of currently marketed drugs. A homology model of CYP2D6 was built using X-ray structures of ligand-bound CYP2C5 complexes as templates. This homology model was used in docking studies to rationalize and predict the site of metabolism of known CYP2D6 substrates. While the homology model was generally found to be in good agreement with the recently solved apo (ligand-free) X-ray structure of CYP2D6, significant differences between the structures were observed in the B' and F-G helical region. These structural differences are similar to those observed between ligand-free and ligand-bound structures of other CYPs and suggest that these conformational changes result from induced-fit adaptations upon ligand binding. By docking to the homology model using Glide, it was possible to identify the correct site of metabolism for a set of 16 CYP2D6 substrates 85% of the time when the 5 top scoring poses were examined. On the other hand, docking to the apo CYP2D6 X-ray structure led to a loss in accuracy in predicting the sites of metabolism for many of the CYP2D6 substrates considered in this study. These results demonstrate the importance of describing substrate-induced conformational changes that occur upon binding. The best results were obtained using Glide SP with van der Waals scaling set to 0.8 for both the receptor and ligand atoms. A discussion of putative binding modes that explain the distribution of metabolic sites for substrates, as well as a relationship between the number of metabolic sites and substrate size, are also presented. In addition, analysis of these binding modes enabled us to rationalize the typical hydroxylation and O-demethylation reactions catalyzed by CYP2D6 as well as the less common N-dealkylation.
引用
收藏
页码:237 / 256
页数:20
相关论文
共 76 条
  • [1] β-Blockers -: The new standard of therapy for mild heart failure
    Abraham, WT
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (09) : 1237 - 1247
  • [2] Revisiting the mechanism of P450 enzymes with the radical clocks norcarane and spiro[2,5]octane
    Auclair, K
    Hu, ZB
    Little, DM
    de Montellano, PRO
    Groves, JT
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (21) : 6020 - 6027
  • [3] Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives
    Bach, MV
    Coutts, RT
    Baker, GB
    [J]. XENOBIOTICA, 1999, 29 (07) : 719 - 732
  • [4] Molecular genetics of CYP2D6:: Clinical relevance with focus on psychotropic drugs
    Bertilsson, L
    Dahl, ML
    Dalén, P
    Al-Shurbaji, A
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (02) : 111 - 122
  • [5] Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
    Bertz, RJ
    Granneman, GR
    [J]. CLINICAL PHARMACOKINETICS, 1997, 32 (03) : 210 - 258
  • [6] Brynne N, 1999, BRIT J CLIN PHARMACO, V48, P553
  • [7] Chow T, 1999, DRUG METAB DISPOS, V27, P1200
  • [8] MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist
    Cruciani, G
    Carosati, E
    De Boeck, B
    Ethirajulu, K
    Mackie, C
    Howe, T
    Vianello, R
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (22) : 6970 - 6979
  • [9] The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans
    Danielson, PB
    [J]. CURRENT DRUG METABOLISM, 2002, 3 (06) : 561 - 597
  • [10] MolProbity: structure validation and all-atom contact analysis for nucleic acids and their complexes
    Davis, IW
    Murray, LW
    Richardson, JS
    Richardson, DC
    [J]. NUCLEIC ACIDS RESEARCH, 2004, 32 : W615 - W619